-
2A Pharma receives approval for phase 1 study of 2AP01
2A Pharma has received approval from the UK Medicines and Healthcare products Regulatory Authority and from the local Ethics Committee to proceed with a first-in-human study of 2AP01, which is being developed as broad coverage prophylactic HPV vaccine formulated without adjuvants. 2A Pharma expects that screening of volunteers will commence... -
Eurostars funding for therapeutic head and neck cancer vaccine project
We are extremely pleased to announce that 2A Pharma in collaboration with partners from The Danish Technological Institute and Danish biotech company DNA Sense have been granted EUR 653,000 Eurostars funding for 2AP07 , a project to develop a therapeutic head and neck cancer vaccine. Head and neck cancers represent the sixth most... -
See our presentation at BIO Europe 2018 on Tuesday, 6 November at 4.30pm
2A Pharma is very happy to announce that we will present at BIO Europe 2018. Please join us on Tuesday, 6 November 2018 at 4.30pm in room B3 (level 0). -
2A Pharma secures SEK 20 million of funding
2A Pharma is very pleased to announce that it has raised SEK 20 million (USD 2.2M) from existing and new investors. This funding augments the previously raised SEK 27 million (USD 3M) and will enable 2A Pharma to drive its leading vaccine candidate, 2AP01, a broad coverage prophylactic HPV vaccine... -
-
BIO Europe Spring 2018
2A Pharma is overwhelmed by the positive responses we received from potential partners and collaborators at BIO-Europe Spring 2018. The conference was a resounding success from our perspective and we are looking forward to continuing the many exciting conversations that were started. -
-
Article about 2A Pharma in MedWatch
The following article was published in Danish pharma industry publication MedWatch on 16 January 2017. Click here to read the article (paywall). -
Exclusive worldwide license agreement
Medigene AG today announced that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus-like particles (AAVLPs) technology to 2A Pharma AB. -
First financing round closed
2A Pharma AB today closed its first financing round, raising SEK 27 million from private angel investors. This new capital will enable us to take our first project, the AAVLP-HPV vaccine, through to the end of phase I clinical studies. We are grateful for our investors’ support and trust.
